Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-13. Numbers and descriptions here follow the published literature rather than marketing material.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
== See also == Plasmid Viral vector Cloning vector Expression vector Hybrid vector Minicircle Recombinant DNA Naked DNA Vector (epidemiology), an organism that transmits disease Human artificial chromosomes Yeast artificial chromosomes Bacterial artificial chromosomes DNA vaccination
Polymeric monoliths as they exist today were developed independently by three different labs in the late 1980s led by Hjerten, Svec, and Tennikova. Simultaneously, bioseparations became increasingly important, and monolith technologies proved beneficial in biotechnology separations. Though industry focus in the 1980s was on biotechnology, focus in the 1990s shifted to process engineering. While mainstream chromatographers were using 3μm particulate columns, sub-2μm columns were in research phase. The smaller particles meant better resolution and shorter run times; there was also an associated increase in backpressure. In order to withstand the pressure, a new field of chromatography came into being: UHPLC or UPLC- ultra high pressure liquid chromatography. The new instruments were able to endure pressures of up to 15,000 pounds per square inch (1,000 bar), as opposed to conventional machines, which, as previously state, can hold up to 5,000 pounds per square inch (340 bar). UPLC is an alternative solution to the same problems monolithic columns solve. Similarly to UPLC, monolith chromatography can help the bottom line by increasing sample throughput, but without the need to spend capital on new equipment. In 1996, Nobuo Tanaka, at the Kyoto Institute of Technology, prepared silica monoliths using a colloidal suspension synthesis (aka “sol-gel”) developed by a colleague. The process is different from that used in polymeric monoliths. Polymeric monoliths, as mentioned above, are created in situ, using a mixture of monomers and a porogen within the column tubing.
=== 1990 === 5 August The Nuts and Bolts of Ben Bowlby, 23 year old Ben Bowlby; his sister Sophie studied costume design; his father was a photographer at the Royal Free Hospital; the first fifteen minutes would be shown as part of the November 1991 episode; monocoque structures; his child psychiatrist grandfather John Bowlby, the son of Sir Anthony Bowlby; Frank Dernie at Team Lotus in Norfolk, and automotive diffusers; circuits at Snetterton Circuit. Narrated by Martin Jarvis, directed by Patrick Uden, made by Uden Associates 12 August The Greenhouse Conspiracy 19 August Selling the Secret, about the Soviet Union selling technology; it visited the Khrunichev State Research and Production Space Center in Moscow. Produced by Paul Murricane, directed by Ross Wilson, made by Scottish Television 2 September Blue Skies, about British innovation and its funding; biologist Nigel R.
Sources: en.wikipedia.org
This dish first became popular in the Heian period of Japan, when water was most commonly poured over rice, but beginning in the Edo period, green tea (particularly bancha and sencha) became a popular substitute due to its aroma and mild umami flavor. It is said that the direct ancestor of today's chazuke is a method of eating that was adopted by servants (apprentices) who were employed by merchants at that time so that they could finish their meal very quickly during their work. At that time, the servants spent most of their day working, and their meal times were controlled by their superiors, so this form of eating naturally arose. Pickles were almost the only side dish that the apprentices were allowed to eat freely in the simple meals, and they were often piled up in huge bowls. Since there was still no technology to keep cooked rice warm as it is today, chazuke was a convenient way to enjoy cold rice and to finish a meal quickly.
Global Navigation Satellite System (GNSS) or satnav system – A system of satellites which allows geographical location on Earth (latitude, longitude, and altitude/elevation) to be determined to high precision (within a few metres) by small portable navigation instruments, by timing the arrival of radio signals from the satellites. These are the most widely used navigation systems today. The main satellite navigation systems are the US Global Positioning System (GPS), Russia's GLONASS, China's BeiDou Navigation Satellite System (BDS) and the European Union's Galileo.
regulon A group of non-contiguous genes which are regulated as a unit, generally by virtue of having their expression controlled by the same regulatory element or set of elements, e.g. the same repressor or activator. The term is most commonly used with prokaryotes, where a regulon may consist of genes from multiple operons.
Sources: en.wikipedia.org
== History == The center was conceived in 2006. Construction began in 2013 after securing funding from the European Regional Development Fund (ERDF) and Czech state grants, with the facility opening in phases between 2015-2016. During the COVID-19 pandemic, BIOCEV’s laboratories were repurposed for PCR testing for regional health authorities. In 2021, the original legal entity (BIOCEV z.s.p.o.) was dissolved, though research operations continued under CAS and Charles University management.
== Medical uses == Heartburn, acid indigestion, and sour stomach Treatment for gastric and duodenal ulcers Treatment for pathologic gastrointestinal hypersecretory conditions such as Zollinger–Ellison syndrome and multiple endocrine adenomas Treatment for gastroesophageal reflux disease (GERD) Treatment for esophagitis Part of a multidrug regimen for Helicobacter pylori eradication, although omeprazole may be somewhat more effective. Prevention of NSAID-induced peptic ulcers. Given to surgery patients before operations to reduce the risk of aspiration pneumonia.
==== Prophecies and statements ==== In 2013, Bakker wrote Time Has Come: How to Prepare Now for Epic Events Ahead about end-time events. Bakker has changed his views on prosperity theology. In his 1980 book Eight Keys to Success, he stated, "God wants you to be happy, God wants you to be rich, God wants you to prosper." In his 1996 book, I Was Wrong, he admitted that the first time he actually read the Bible all the way through was in prison. Bakker also wrote that he realized that he had taken passages out of context and used them as prooftexts to support his prosperity theology. Bakker's revived show features a number of ministers who bill themselves as "prophets". He now says that "PTL" stands for "Prophets Talking Loud". In an October 2017 video, Bakker said that "God will punish those" who ridicule him; he has said that Hurricane Harvey was a judgment of God, and he blamed Hurricane Matthew on then-President Barack Obama. Bakker predicted that if then-President Donald Trump was impeached, Christians would begin a Second American Civil War. He compared the 2017 Washington train derailment to the sinking of the RMS Titanic and stated the Amtrak train derailment was a warning from God. He also claimed that he predicted the September 11 attacks of 2001, stating that he "saw 9/11 in 1999 before New Year's Eve" and that there would "be terrorism" and bombings in New York City and Washington, D.C. A few days after the Stoneman Douglas High School shooting, he stated that "God came to [him] in a dream...
The ability to control the size, flow rate, and composition of droplets provides an option to fine tune the morphology of fibers to fit a specific use in bioanalysis and emulation of anatomical functions.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.